UroToday

ESMO 2026: Phase 3 Study to Assess the Safety and Efficacy of 177Lu-Girentuximab in Advanced, Relapsed or Recurrent ccRCC (LUTEON)

(UroToday.com) At the 2026 European Society for Medical Oncology (ESMO) Annual Congress, Dr. Laurence Albiges and colleagues presented the study design of LUTEON, an ongoing, randomized phase III ...
UroToday

ESMO 2026: Impact of Enzalutamide-Related Drug–drug Interactions on Adverse Events in the EORTC 1333-GUCG PEACE-3 Trial

The 2026 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Mehdi Bsilat discussing the impact ...
UroToday

ESMO 2026: Is Consolidative Treatment Needed in Clinical Complete Response?

Radical cystectomy remains a major operation even at experienced centers and with robotic surgical techniques. Data from the ...
UroToday

Johnson & Johnson Reports 75% Tumor Response Rate in Advanced Prostate Cancer with JNJ-6143, a First-in-Class RIPTAC™ Molecule

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a highly expressed ...
UroToday

The Optimal Treatment for Gleason Score 9-10 Prostate Cancer

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
UroToday

ESMO 2026: Association Between Prior Treatment Exposure and Genomic Alterations in mCRPC: An Ancillary Study of the ProBio Trial

(UroToday.com) The 2026 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Alexander Decruyenaere discussing an ancillary study of the ProBio trial assessing the ...